Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Acta Médica Peruana
versión On-line ISSN 1728-5917
Resumen
TERASHIMA, Angélica y MARCOS, Luis A. Failure of single-dose triclabendazole in the therapy of human fasciolasis. Acta méd. Peru [online]. 2016, vol.33, n.3, pp.228-231. ISSN 1728-5917.
Human fascioliasis is prevalent in cattle raising areas in Peru. The only effective drug against Fasciola hepatica infections in clinical practice is triclabendazole (TCBZ). However, the occurrence of TCBZ-resistant F. hepatica both in humans and animals has recently been reported in Peru. This issue was previously suspected, due to treatment failure (presence of Fasciola eggs after treatment) in some patients receiving a single dose of TCBZ. Here, we report 11 of 12 human cases infected by F. hepatica who did not respond to TCBZ administered in a single 10 mg/Kg oral dose. Given these results observed in clinical practice, we recommend the use of at least two doses of TCBZ for human fascioliasis. Nowadays, the treatment for fascioliasis has become an emergent problem from the pharmacological point of view. New therapies against Fasciola are urgently needed
Palabras clave : Fasciola hepatica; Triclabendazole; Resistance; Feces.